Показать сокращенную информацию

dc.contributor.authorYekta, Z.
dc.contributor.authorPourali, R.
dc.contributor.authorTaravati, M.R.
dc.contributor.authorShahabi, S.
dc.contributor.authorSalary, S.
dc.contributor.authorKhalily, F.
dc.contributor.authorFarzin, A.
dc.date.accessioned2014-06-17T08:42:12Z
dc.date.available2014-06-17T08:42:12Z
dc.date.issued2009EN
dc.identifier.issn1020-3397EN
dc.identifier.otherhttp://applications.emro.who.int/emhj/1503/15_3_2009_0516_0525.pdfEN
dc.identifier.urihttps://iris.who.int/handle/10665/117666
dc.description516-525EN
dc.description.abstractWe investigated the effectiveness of the mass measles vaccination campaign in Urmia, Islamic Republic of Iran, by examining the measles IgG seroprevalence and antibody response from paired data before and after the campaign. The overall seropositive rate of 624 subjects aged 5-25 years increased 1 year after the mass vaccination [‎from 53.0% to 72.3%]‎. A rise in antibody titre occurred in all age groups except the 21-25 years group, which had the highest titre before mass vaccination. On logistic regression analysis, only immune status prior to vaccination was significantly associated with the seroresponse. It may be cost-effective to check antibody titres before mass vaccinations, especially in high vaccine coverage regions with circulating wild virusEN
dc.language.isoenEN
dc.subjectMass ImmunizationEN
dc.subjectImmunoglobulin GEN
dc.subjectSeroepidemiologic StudiesEN
dc.subjectCost-Benefit AnalysisEN
dc.subjectEnzyme-Linked Immunosorbent AssayEN
dc.subjectAge FactorsEN
dc.subject.meshMeasles VaccineEN
dc.titleImmune response to measles vaccine after mass vaccination in Urmia, Islamic Republic of IranEN
dc.relation.ispartofjournalEMHJ - Eastern Mediterranean Health Journal, 15 (‎3)‎, 516-525, 2009


Файл

Thumbnail

Коллекция

Показать сокращенную информацию